ÈËÆÞÖгöÊÓƵ

Journal Article

1. Goda C, Kolovich S, Rudich A, Karunasiri M, Kulkarni R, Rajgolikar G, Neidemire-Colley L, Singh S, Sircar A, Ranganathan P, Garzon R, Sehgal L, Dorrance AM (2023). Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma. Exp Hematol. ()
2. Crudele F, Bianchi N, Terrazzan A, Ancona P, Frassoldati A, Gasparini P, DAdamo AP, Papaioannou D, Garzon R, Wjcicka A, Gaj P, Jadewski K, Palatini J, Volinia S (2023). Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways. Biology (Basel), 12(4). ()
3. Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrzek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, Garzon R (2022). Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, 107(5), 1034-1044. ()
4. Dorrance AM, Moutuou MM, Goda C, Sell NE, Kalyan S, Karunasiri M, Kulkarni R, Goulard M, Kolovich S, Rudich A, Naumann E, Ackaoui A, Bigras CE, Daudelin F, Garzon R, Ranganathan P, Guimond M (2021). Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice. Blood Adv, 6(7), 2403-2408. ()
5. Fobare S, Kohlschmidt J, Ozer HG, Mrzek K, Nicolet D, Mims AS, Garzon R, Blachly JS, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Oakes CC, Eisfeld AK, Hertlein E, Byrd JC (2021). Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv, 6(5), 1371-1380. ()
6. Pepe F, Bill M, Papaioannou D, Karunasiri M, Walker A, Naumann E, Snyder K, Ranganathan P, Dorrance A, Garzon R (2022). Targeting Wnt signaling in acute myeloid leukemia stem cells. Haematologica, 107(1), 307-311. ()
7. Di Marcantonio D, Martinez E, Kanefsky JS, Huhn JM, Gabbasov R, Gupta A, Krais JJ, Peri S, Tan Y, Skorski T, Dorrance A, Garzon R, Goldman AR, Tang HY, Johnson N, Sykes SM (2021). ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. Mol Cell, 81(13), 2752-2764.e6. ()
8. Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC (2021). DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Res, 31(5), 747-761. ()
9. Walker CJ, Mrzek K, Ozer HG, Nicolet D, Kohlschmidt J, Papaioannou D, Genutis LK, Bill M, Powell BL, Uy GL, Kolitz JE, Carroll AJ, Stone RM, Garzon R, Byrd JC, Eisfeld AK, de la Chapelle A, Bloomfield CD (2020). Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood Adv, 5(5), 1474-1482. ()
10. Bhatnagar B, Kohlschmidt J, Mrzek K, Zhao Q, Fisher JL, Nicolet D, Walker CJ, Mims AS, Oakes C, Giacopelli B, Orwick S, Boateng I, Blachly JS, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Byrd JC, Paskett ED, de la Chapelle A, Garzon R, Eisfeld AK (2020). Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer Discov, 11(3), 626-637. ()
11. Kuo CT, Lee RJ, Garzon R (2021). Methods Used to Make Lipid Nanoparticles to Deliver LNA Gapmers Against lncRNAs into Acute Myeloid Leukemia (AML) Blasts. Methods Mol Biol, 2348, 167-174. ()
12. Kuo CT, Lee RJ, Garzon R (2021). Correction to: Methods Used to Make Lipid Nanoparticles to Deliver LNA Gapmers Against lncRNAs into Acute Myeloid Leukemia (AML) Blasts. Methods Mol Biol, 2348, C1. ()
13. Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS (2020). A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol, 95(12), 1457-1465. ()
14. Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B (2020). Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. Int J Hematol Oncol, 9(3), IJH28. ()
15. Silvestri G, Trotta R, Stramucci L, Ellis JJ, Harb JG, Neviani P, Wang S, Eisfeld AK, Walker CJ, Zhang B, Srutova K, Gambacorti-Passerini C, Pineda G, Jamieson CHM, Stagno F, Vigneri P, Nteliopoulos G, May PC, Reid AG, Garzon R, Roy DC, Moutuou MM, Guimond M, Hokland P, Deininger MW, Fitzgerald G, Harman C, Dazzi F, Milojkovic D, Apperley JF, Marcucci G, Qi J, Polakova KM, Zou Y, Fan X, Baer MR, Calabretta B, Perrotti D (2020). Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discov, 1(1), 48-67. ()
16. Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, Phelps MA, Walker AR (2020). Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leuk Lymphoma, 61(6), 1484-1492. ()
17. Snyder KJ, Zitzer NC, Gao Y, Choe HK, Sell NE, Neidemire-Colley L, Ignaci A, Kale C, Devine RD, Abad MG, Pietrzak M, Wang M, Lin H, Zhang YW, Behbehani GK, Jackman JE, Garzon R, Vaddi K, Baiocchi RA, Ranganathan P (2020). PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease. JCI Insight, 5(8). ()
18. Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B (2019). Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Invest New Drugs, 38(2), 340-349. ()
19. Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mrzek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield CD (2020). Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European Leukemia Net classification of acute myeloid leukemia. Haematologica, 105(3), 721-9.
20. Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mrzek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield CD (2019). Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European Leukemia Net classification of acute myeloid leukemia. Haematologica, 105(3), 721-729. ()
21. Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R (2019). Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma, 61(2), 387-396. ()
22. Bill M, Pathmanathan A, Karunasiri M, Shen C, Burke MH, Ranganathan P, Papaioannou D, Zitzer NC, Snyder K, LaRocco A, Walker AE, Brannan ZJ, Nalin AP, Freud AG, Dikov MM, Zhang X, Bloomfield CD, Garzon R, Dorrance AM (2019). EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia. Clin Cancer Res, 26(3), 669-678. ()
23. Papaioannou D, Volinia S, Nicolet D, wierniak M, Petri A, Mrzek K, Bill M, Pepe F, Walker CJ, Walker AE, Carroll AJ, Kohlschmidt J, Eisfeld AK, Powell BL, Uy GL, Kolitz JE, Wang ES, Kauppinen S, Dorrance A, Stone RM, Byrd JC, Bloomfield CD, Garzon R (2019). Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Adv, 4(2), 239-251. ()
24. Papaioannou D, Petri A, Dovey OM, Terreri S, Wang E, Collins FA, Woodward LA, Walker AE, Nicolet D, Pepe F, Kumchala P, Bill M, Walker CJ, Karunasiri M, Mrzek K, Gardner ML, Camilotto V, Zitzer N, Cooper JL, Cai X, Rong-Mullins X, Kohlschmidt J, Archer KJ, Freitas MA, Zheng Y, Lee RJ, Aifantis I, Vassiliou G, Singh G, Kauppinen S, Bloomfield CD, Dorrance AM, Garzon R (2019). The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. Nat Commun, 10(1), 5351. ()
25. Bill M, Papaioannou D, Karunasiri M, Kohlschmidt J, Pepe F, Walker CJ, Walker AE, Brannan Z, Pathmanathan A, Zhang X, Mrzek K, LaRocco A, Volinia S, Bloomfield CD, Garzon R, Dorrance AM (2019). Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. Leukemia, 33(9), 2169-2182. ()
26. Papaioannou D, Nicolet D, Ozer HG, Mrzek K, Volinia S, Fadda P, Carroll AJ, Kohlschmidt J, Kolitz JE, Wang ES, Stone RM, Byrd JC, Garzon R, Bloomfield CD (2019). Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. Mol Cancer Ther, 18(8), 1451-1459. ()
27. Efebera YA, Ruppert AS, Ngankeu A, Garman S, Kumchala P, Howard A, Devine SM, Ranganathan P, Garzon R (2019). Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD). 2, 079-82. ()
28. Lovat F, Fassan M, Sacchi D, Ranganathan P, Palamarchuk A, Bill M, Karunasiri M, Gasparini P, Nigita G, Distefano R, Veneziano D, Dorrance AM, Garzon R, Croce CM (2018). Knockout of both miR-15/16 loci induces acute myeloid leukemia. Proc Natl Acad Sci U S A, 115(51), 13069-13074. ()
29. Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R, Ranganathan P (2018). MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. J Immunol, 200(12), 4170-4179. ()
30. Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W (2018). A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica, 103(6), 982-987. ()
31. Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Frhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM (2017). Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res, 24(3), 608-618. ()
32. Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R (2017). Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget, 9(4), 4354-4365. ()
33. Papaioannou D, Nicolet D, Volinia S, Mrzek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD (2017). Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica, 102(8), 1391-1400. ()
34. He Z, Hu X, Liu W, Dorrance A, Garzon R, Houghton PJ, Shen C (2016). P53 suppresses ribonucleotide reductase via inhibiting mTORC1. Oncotarget, 8(25), 41422-41431. ()
35. Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R (2017). A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood, 129(24), 3165-3174. ()
36. Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood, 129(24), 3175-3183. ()
37. Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrzek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM (2017). Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A, 114(23), E4641-E4647. ()
38. Zhou X, Liu W, Hu X, Dorrance A, Garzon R, Houghton PJ, Shen C (2017). Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep, 7(1), 1535. ()
39. Ranganathan P, Ngankeu A, Zitzer NC, Leoncini P, Yu X, Casadei L, Challagundla K, Reichenbach DK, Garman S, Ruppert AS, Volinia S, Hofstetter J, Efebera YA, Devine SM, Blazar BR, Fabbri M, Garzon R (2017). Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. J Immunol, 198(6), 2500-2512. ()
40. Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Dorrance AM, Blum W, Sampath D, Landesman Y, Garzon R (2016). XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus. Clin Cancer Res, 22(24), 6142-6152. ()
41. Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R (2016). Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia, 30(12), 2364-2372. ()
42. Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L, Blazar BR (2016). miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood, 128(10), 1424-35. ()
43. Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci G (2016). Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma, 57(9), 2100-8. ()
44. Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Patel M, Bainazar MA, Huang X, Lankenau MA, Hoag KW, Ranganathan P, Garzon R, Blachly JS, Guttridge DC, Bloomfield CD, de la Chapelle A, Eisfeld AK (2016). Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. Cancer Discov, 6(9), 1036-51. ()
45. Bhatnagar B, Garzon R (2016). Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine? Biomark Med, 10(9), 935-8. ()
46. Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, DOvidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon R (2016). MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget, 7(34), 55395-55408. ()
47. Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D (2016). HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clin Cancer Res, 22(14), 3537-49. ()
48. Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK (2016). Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. AAPS J, 18(3), 737-45. ()
49. Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi RA, Marcucci G (2015). The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia, 30(4), 789-99. ()
50. Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, ODonnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM (2015). Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). Biol Blood Marrow Transplant, 22(1), 71-9. ()
51. Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci G (2015). Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia, 29(11), 2143-53. ()
52. Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia, 29(10), 1981-92. ()
53. Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R (2015). Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood, 125(17), 2689-92. ()
54. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrzek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD (2014). Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A, 111(52), 18679-84. ()
55. Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corr F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon R (2014). Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. J Natl Cancer Inst, 106(12). ()
56. Galasso M, Dama P, Previati M, Sandhu S, Palatini J, Coppola V, Warner S, Sana ME, Zanella R, Abujarour R, Desponts C, Teitell MA, Garzon R, Calin G, Croce CM, Volinia S (2014). A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. Genome Med, 6(10), 76. ()
57. Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum W (2013). Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma, 55(6), 1304-8. ()
58. Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R (2014). Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood, 123(15), 2412-5. ()
59. Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrzek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G (2014). SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest, 124(4), 1512-24. ()
60. Mishra A, Garzon R (2014). The (miR)e of CTCL. Blood, 123(10), 1438. ()
61. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrzek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Br C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CD (2013). Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol, 32(6), 548-56. ()
62. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D (2013). Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood, 122(17), 3034-44. ()
63. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D (2013). PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest, 123(10), 4144-57. ()
64. Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W (2013). Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma, 54(9), 1996-2002. ()
65. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrzek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD (2013). Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol, 31(17), 2086-93. ()
66. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M (2013). CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest, 123(6), 2395-407. ()
67. Phillips CL, Davies SM, McMasters R, Absalon M, OBrien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP (2013). Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in ÈËÆÞÖгöÊÓƵren and young adults. Br J Haematol, 161(3), 406-10. ()
68. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G (2013). Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res, 19(9), 2355-67. ()
69. Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrzek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G (2012). Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia, 27(4), 871-8. ()
70. Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G (2013). Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol, 6, 21. ()
71. Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrzek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G (2012). Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood, 121(1), 159-69. ()
72. Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G (2012). In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. AAPS J, 15(1), 242-9. ()
73. Sandhu SK, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G, Garzon R, Croce CM (2012). miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci U S A, 109(49), 20047-52. ()
74. Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, Wu YZ, Heerema NA, Chan KK, Perrotti D, Zhang J, Porcu P, Racke FK, Garzon R, Lee RJ, Marcucci G, Caligiuri MA (2011). Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell, 22(5), 645-55. ()
75. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA, National Comprehensive Cancer Network (2012). Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw, 10(11), 1412-45. ()
76. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh R, Marcucci G (2012). Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood, 120(12), 2466-74. ()
77. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R (2012). Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood, 120(9), 1765-73. ()
78. Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci G (2012). Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood, 119(25), 6025-31. ()
79. Wang H, Chiu M, Xie Z, Chiu M, Liu Z, Chen P, Liu S, Byrd JC, Muthusamy N, Garzon R, Croce CM, Marcucci G, Chan KK (2012). Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. Mol Pharm, 9(6), 1638-44. ()
80. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shanaah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R (2012). Regulation of acute graft-versus-host disease by microRNA-155. Blood, 119(20), 4786-97. ()
81. Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM (2011). Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematol Oncol, 29(4), 202-10. ()
82. Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G, Croce CM, Garzon R (2011). Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer, 117(20), 4696-706. ()
83. Schwind S, Maharry K, Radmacher MD, Mrzek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD (2010). Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol, 28(36), 5257-64. ()
84. Chan KK, Liu Z, Xie Z, Chiu M, Wang H, Chen P, Dunkerson S, Chiu M, Liu S, Triantafillou G, Garzon R, Croce CM, Byrd JC, Muthusamy N, Marcucci G (2010). A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application. AAPS J, 12(4), 556-68. ()
85. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC (2010). Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol, 28(33), 4919-25. ()
86. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM (2010). Reprogramming of miRNA networks in cancer and leukemia. Genome Res, 20(5), 589-99. ()
87. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G (2010). Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A, 107(16), 7473-8. ()
88. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G (2009). Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell, 17(4), 333-47. ()
89. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D (2009). miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell, 140(5), 652-65. ()
90. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM (2009). MicroRNA 29b functions in acute myeloid leukemia. Blood, 114(26), 5331-41. ()
91. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, ODonnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM (2009). Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant, 15(11), 1422-30. ()
92. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G (2009). MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 113(25), 6411-8. ()
93. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2009). Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem, 284(23), 15676-84. ()
94. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM (2009). Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant, 15(5), 547-53. ()
95. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC (2008). NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell, 14(5), 369-81. ()
96. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A, 105(35), 12885-90. ()
97. Marcucci G, Radmacher MD, Maharry K, Mrzek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD (2008). MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med, 358(18), 1919-28. ()
98. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A, 105(13), 5166-71. ()
99. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM (2008). MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 111(6), 3183-9. ()
100. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B (2008). Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A, 105(10), 3945-50. ()
101. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G (2007). Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood, 111(4), 2364-73. ()
102. Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM (2007). Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. Transpl Infect Dis, 10(1), 24-6. ()
103. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A, 104(40), 15805-10. ()
104. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, Calin GA, Liu CG, Andreeff M, Croce CM (2007). MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene, 26(28), 4148-57. ()
105. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M (2006). A microRNA signature of hypoxia. Mol Cell Biol, 27(5), 1859-67. ()
106. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM (2006). MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A, 103(13), 5078-83. ()
107. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med, 353(17), 1793-801. ()
108. Garzon R, Murphy JM (2002). Acute bulbar muscle dysfunction in hyperthyroidism. Conn Med, 66(1), 3-6. ()
109. Mirza I, Garzn R, Burns J, Edwards L, Fernandez-Cymering C, Kloss R (2001). Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System. Conn Med, 65(8), 455-63. ()

Review

1. Bhatnagar B, Garzon R (2021). Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review. [Review]. Front Oncol, 11, 679022. ()
2. Walker JS, Garzon R, Lapalombella R (2020). Selinexor for advanced hematologic malignancies. [Review]. Leuk Lymphoma, 61(10), 2335-2350. ()
3. Zitzer NC, Garzon R, Ranganathan P (2018). Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease. [Review]. Front Immunol, 9, 2561. ()
4. Saultz JN, Garzon R (2016). Acute Myeloid Leukemia: A Concise Review. [Review]. J Clin Med, 5(3). ()
5. Bhatnagar B, Garzon R (2014). The use of molecular genetics to refine prognosis in acute myeloid leukemia. [Review]. Curr Hematol Malig Rep, 9(2), 148-57. ()
6. Garzon R, Marcucci G (2012). Potential of microRNAs for cancer diagnostics, prognostication and therapy. [Review]. Curr Opin Oncol, 24(6), 655-9. ()
7. Sandhu S, Garzon R (2011). Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. [Review]. Semin Oncol, 38(6), 781-7. ()
8. Marcucci G, Mrzek K, Radmacher MD, Garzon R, Bloomfield CD (2010). The prognostic and functional role of microRNAs in acute myeloid leukemia. [Review]. Blood, 117(4), 1121-9. ()
9. Havelange V, Garzon R (2010). MicroRNAs: emerging key regulators of hematopoiesis. [Review]. Am J Hematol, 85(12), 935-42. ()
10. Garzon R, Marcucci G, Croce CM (2010). Targeting microRNAs in cancer: rationale, strategies and challenges. [Review]. Nat Rev Drug Discov, 9(10), 775-89. ()
11. Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu P (2009). New targets of therapy in T-cell lymphomas. [Review]. Curr Drug Targets, 11(4), 482-93. ()
12. Havelange V, Garzon R, Croce CM (2009). MicroRNAs: new players in acute myeloid leukaemia. [Review]. Br J Cancer, 101(5), 743-8. ()
13. Garzon R (2008). MicroRNA profiling of megakaryocytes. [Review]. Methods Mol Biol, 496, 293-8. ()
14. Garzon R, Calin GA, Croce CM (2009). MicroRNAs in Cancer. [Review]. Annu Rev Med, 60, 167-79. ()
15. Garzon R, Croce CM (2008). MicroRNAs in normal and malignant hematopoiesis. [Review]. Curr Opin Hematol, 15(4), 352-8. ()
16. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA (2008). MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. [Review]. Leukemia, 22(6), 1095-105. ()
17. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM (2006). MicroRNA expression and function in cancer. [Review]. Trends Mol Med, 12(12), 580-7. ()
18. Robles AM, Casas JP, Pereyra MA, Garzn R, Lpez AM (2001). [Acute eosinophilic pneumonia. Case report and review of the literature]. [Review]. Medicina (B Aires), 60(5 Pt 1), 605-8. ()

Editorial

1. Garzon R, Croce CM (2011). MicroRNAs and cancer: introduction. Semin Oncol, 38(6), 721-3. ()
2. Calin GA, Garzon R, Cimmino A, Fabbri M, Croce CM (2005). MicroRNAs and leukemias: how strong is the connection? Leuk Res, 30(6), 653-5. ()

Letter

1. Bill M, Goda C, Pepe F, Ozer HG, McNeil B, Zhang X, Karunasiri M, Kulkarni R, Kalyan S, Papaioannou D, Ferenchak G, Garzon R, Bradner JE, Marcucci G, Caligiuri MA, Dorrance AM (2021). Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the MLL gene. [Letter to the editor]. Haematologica, 106(9), 2527-2532. ()
2. Bill M, Mrzek K, Giacopelli B, Kohlschmidt J, Nicolet D, Papaioannou D, Eisfeld AK, Kolitz JE, Powell BL, Carroll AJ, Stone RM, Garzon R, Byrd JC, Bloomfield CD, Oakes CC (2021). Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. [Letter to the editor]. J Hematol Oncol, 14(1), 107. ()
3. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G (2011). DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. [Letter to the editor]. Leukemia, 26(5), 1106-7. ()

Patent

1. Garzon R, Papaioannou D, Dorrance A, Lee R (2020). Targeting HOXB-AS3 in AML. U.S. Patent No. 10787665B2. Washington, D.C.:U.S. Patent and Trademark Office.
2. Garzon R, Croce CM, Calin GA (2014). MicroRNA Fingerprints during Human Megakaryocytopoiesis. U.S. Patent No. 7985584-B12. Washington, D.C.:U.S. Patent and Trademark Office.
3. Croce CM, Garzon R (2014). MicroRNAs associated with cytogenetics and outcome in acute myeloid leukemia. U.S. Patent No. PCT/US/2009/035482. Washington, D.C.:U.S. Patent and Trademark Office.

Huntsman Cancer Institute News

• Ramiro Garzon, MD, to Lead Hematologic Cancers at Huntsman Cancer Institute and ÈËÆÞÖгöÊÓƵ of Utah ÈËÆÞÖгöÊÓƵ